宋莉,姚晶,周鹏,刘臣,谭宇,盛兆雪,李健楠,周金英,陈润真,赵汉军,颜红兵

• 1:国家心血管病中心北京协和医学院中国医学科学院阜外医院冠心病中心
• 2:鹤岗市人民医院心内二科

摘要(Abstract)：

目的比较应用替格瑞洛和氯吡格雷治疗的ST段抬高型心肌梗死(STEMI)行急诊经皮冠状动脉介入治疗(PCI)患者的基线特征、疗效和安全性。方法入选2017年3月至2018年6月于中国医学科学院阜外医院行急诊PCI的STEMI患者537例。按入院时服用P2Y12抑制药的种类分为替格瑞洛组(299例)和氯吡格雷组(238例)。比较两组患者基线特征以及6个月主要不良心血管事件和出血风险。结果替格瑞洛组PCI史、支架内再狭窄和支架内血栓形成比例、使用抽吸导管和血小板糖蛋白Ⅱb/Ⅲa抑制药比例均偏高(均P<0.05)。替格瑞洛组合用的阿司匹林剂量偏低[(79.7±14.9)mg/d比(95.8±16.8)mg/d,P<0.001];而氯吡格雷组患者年龄偏大,体重偏轻,女性比例高,卒中比例高,血红蛋白、血小板计数和肌酐清除率水平偏低,心肌梗死溶栓治疗试验(TIMI)评分、全球急性冠状动脉事件注册(GRACE)评分和不稳定型心绞痛快速风险分层减少早期执行ACC/AHA指南的不良结果(CRUSADE)评分均偏高(均P<0.05)。logistic多因素回归分析显示,年龄(OR 0.960,95%CI 0.936～0.985,P=0.002)和PCI史(OR 1.849,95%CI 1.091～3.135,P=0.022)是入院时选择替格瑞洛治疗的独立预测因素。替格瑞洛组全因死亡、心肌梗死和缺血性卒中的联合终点发生率低于氯吡格雷组(3.0%比8.0%,P=0.016),而总体出血(35.5%比19.8%)和轻微出血(31.8%比13.5%)发生率显著高于氯吡格雷组(均P<0.001)。结论应用替格瑞洛治疗的STEMI急诊PCI患者比例已超过50%,年龄和PCI史是入院时选择替格瑞洛治疗的独立预测因素。替格瑞洛降低了缺血事件发生率,同时增加了出血发生率,但主要为轻微出血。

关键词(KeyWords)： 心肌梗死;P2Y12抑制药;替格瑞洛;氯吡格雷

Abstract:

Keywords:

基金项目(Foundation): 中国医学科学院医学与健康科技创新工程(2016-I2M-1-009)

作者(Author): 宋莉,姚晶,周鹏,刘臣,谭宇,盛兆雪,李健楠,周金英,陈润真,赵汉军,颜红兵

参考文献(References)：

• [1] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009, 361(11):1045-1057.
• [2] Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials:a consensus report from the Bleeding Academic Research Consortium. Circulation, 2011, 123(23):2736-2747.
• [3] Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007, 357(20):2001-2015.
• [4] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for CardioThoracic Surgery(EACTS). Eur Heart J, 2018, 39(3):213-260.
• [5] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2016, 68(10):1082-1115.
• [6]中华医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南（2016）.中华心血管病杂志，2016, 44(5):382-400.
• [7] Gao R, Wu Y, Liu H, et al. Safety and incidence of cardiovascular events in Chinese patients with acute coronary syndrome treated with ticagrelor:the 12-month, phase IV, multicenter, single-arm DAYU study. Cardiovasc Drugs Ther, 2018, 32(1):47-56.
• [8] Basra SS, Wang TY, Simon DN, et al. Ticagrelor use in acute myocardial infarction:insights from the national Cardiovascular data registry. J Am Heart Assoc, 2018, 7(12). pii:e008125.
• [9] Yudi MB, Clark DJ, Farouque O, et al. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Intern Med J, 2016, 46(5):559-565.
• [10] Esteve-Pastor MA, Ruíz-Nodar JM, Orenes-Pifiero E, et al.Temporal trends in the use of antiplatelet therapy in patients with acute coronary syndromes. J Cardiovasc Pharmacol Ther, 2018, 23:57-65.